Peer-reviewed veterinary case report
How to Detect CaniLeish Vaccination in Dogs Using Blood Tests
By Lima, Carla et al.·Published in Frontiers in veterinary science·2019·i3S - Instituto de Investigaç·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs.
- Species:
- dog
Plain-English summary
A group of 20 healthy dogs were vaccinated against canine leishmaniosis (a disease spread by sandflies) and monitored for two years to see how the vaccine affected their blood tests. After the study period, all vaccinated dogs showed a positive response to a specific test (SPLA), which helped differentiate them from both infected and unvaccinated dogs. This means that the vaccine not only helps protect dogs from the disease but also allows for more accurate testing in the future. The findings suggest that the CaniLeish vaccine is effective in preventing the disease and can be useful in monitoring dog health.
People also search for: dog leishmaniasis vaccine · CaniLeish effectiveness · canine leishmaniosis blood test
Abstract
Canine leishmaniosis (CanL) prevention in the Mediterranean basin is considered essential to stop human zoonotic visceral leishmaniasis. In this context, vaccination of dogs is expected to have a significant impact in disease control. CaniLeish® (Virbac Animal Health) is one of a few CanL vaccines that are at this moment licensed in Europe. This vaccine contains purified excreted-secreted proteins ofhaving several antigens/immunogens with potential to influence serological response. Therefore, it is important to know if CaniLeish vaccination increased the diagnostic challenges associated with conventional serology, limiting the value of some antigens. To address this 20 dogs from a cohort of 35 healthy dogs that were vaccinated, maintained indoor for 1 month and then returned to their natural domiciles for 2 years. After this period, they were re-called to evaluate their clinical/parasitological condition and assess the evolution of seroreactivity against different antigens: soluble promastigoteantigens (SPLA), recombinant proteincytosolic peroxiredoxin, recombinant protein K39 (rK39), recombinant protein K28 and recombinant kinesin degenerated derived repeat using ELISA. Two years after vaccination all vaccinated non-infected animals were seropositive for SPLA. For the other antigens the serological profile was indistinguishable from non-infected animals. Moreover, vaccinated animals presented a characteristic relative serological profile, with higher normalized serological response to SPLA than rK39. This fact enabled to distinguish with sensitivity 92.3% and specificity 95.4%, vaccinated non-infected dogs from infected and non-infected dogs. Ultimately, relative serological profile enabled the detection of healthy vaccinated animals enabling more accurate serological surveys.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31709270/